This ready-to-use antibody blocking and diluent buffer formulation has been optimized specifically for Opal™ and TSA® Plus immunohistochemistry protocols.
This product reacts specifically with primary antibodies raised in mouse and rabbit and is part of a rapid, biotin-free detection protocol. Quantitative results may be obtained with careful optimization of the primary antibody con...
TSA Biotin kits are complete tyramide signal amplification kits that include Biotin tyramide, amplification diluent, streptavidin HRP, blocking reagent and comprehensive instruction manuals.
TSA Plus DNP technology uses HRP to catalyze the deposition of the dinitrophenyl (DNP) labeled amplification reagent onto tissue sections or cell preparation surfaces that have been previously blocked with proteins.
TSA Plus DIG uses horseradish peroxidase (HRP) to catalyze covalent deposition of digoxigenin (DIG) labels directly adjacent to the immobilized enzyme.
TSA® Plus Cyanine 3 (TSA Cy3) detection kit, for amplification of signal in immunohistochemistry (IHC), immunofluorescence (IF) or in situ hybridization protocols.
TSA® Plus Cyanine 3.5 (Cy3.5) detection kit, for amplification of signal in immunohistochemistry (IHC), immunofluorescence (IF) or in situ hybridization protocols.
TSA® Plus Cyanine 5 (TSA Cy5) detection kit, for amplification of signal in immunohistochemistry (IHC), immunofluorescence (IF) or in situ hybridization protocols.
TSA® Plus Cyanine 5.5 (Cy5.5) detection kit, for amplification of signal in immunohistochemistry (IHC), immunofluorescence (IF) or in situ hybridization protocols.
TSA® Plus fluorescein detection kit, for amplification of signal in immunohistochemistry (IHC), immunofluorescence (IF) or in situ hybridization protocols.
TSA® Plus tetramethylrhodamine (TMR) detection kit, for amplification of signal in immunohistochemistry (IHC), immunofluorescence (IF) or in situ hybridization protocols.
PhenoCode Signature Immuno-Contexture panel (CD8, CD68, PD-L1, FoxP3, PanCK) enables profiling of the tumor microenvironment for CD8+ T lymphocytes and PD-L1 expression.